{"title":"视网膜血管炎与玻璃体内注射贝伐单抗:1例报告。","authors":"S Murillo-Lopez, S Medina-Medina","doi":"10.1016/j.oftale.2025.03.011","DOIUrl":null,"url":null,"abstract":"<p><p>Anti-vascular endothelial growth factor drugs are the treatment of choice for macular edema due to venous occlusions. While rare, they have been associated with some uncommon adverse effects. We present a case of retinal vasculitis associated with bevacizumab in a72-year-old woman who presented to our clinic with sudden visual acuity loss in her left eye due to macular edema following central vein occlusion. She was treated with bevacizumab, with a minor inflammatory response that resolved with topical steroids. After 6 weeks, the macular edema recurred and a 2<sup>nd</sup> dose of bevacizumab was indicated, with a severe inflammatory reaction that resolved with periocular steroids and topical NSAIDs. Systemic vasculitis and infectious diseases were ruled out and treatment was switched to aflibercept with no adverse effects being reported.</p>","PeriodicalId":93886,"journal":{"name":"Archivos de la Sociedad Espanola de Oftalmologia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Retinal vasculitis associated with intravitreal bevacizumab injection: A case report.\",\"authors\":\"S Murillo-Lopez, S Medina-Medina\",\"doi\":\"10.1016/j.oftale.2025.03.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Anti-vascular endothelial growth factor drugs are the treatment of choice for macular edema due to venous occlusions. While rare, they have been associated with some uncommon adverse effects. We present a case of retinal vasculitis associated with bevacizumab in a72-year-old woman who presented to our clinic with sudden visual acuity loss in her left eye due to macular edema following central vein occlusion. She was treated with bevacizumab, with a minor inflammatory response that resolved with topical steroids. After 6 weeks, the macular edema recurred and a 2<sup>nd</sup> dose of bevacizumab was indicated, with a severe inflammatory reaction that resolved with periocular steroids and topical NSAIDs. Systemic vasculitis and infectious diseases were ruled out and treatment was switched to aflibercept with no adverse effects being reported.</p>\",\"PeriodicalId\":93886,\"journal\":{\"name\":\"Archivos de la Sociedad Espanola de Oftalmologia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-03-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archivos de la Sociedad Espanola de Oftalmologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.oftale.2025.03.011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archivos de la Sociedad Espanola de Oftalmologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.oftale.2025.03.011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Retinal vasculitis associated with intravitreal bevacizumab injection: A case report.
Anti-vascular endothelial growth factor drugs are the treatment of choice for macular edema due to venous occlusions. While rare, they have been associated with some uncommon adverse effects. We present a case of retinal vasculitis associated with bevacizumab in a72-year-old woman who presented to our clinic with sudden visual acuity loss in her left eye due to macular edema following central vein occlusion. She was treated with bevacizumab, with a minor inflammatory response that resolved with topical steroids. After 6 weeks, the macular edema recurred and a 2nd dose of bevacizumab was indicated, with a severe inflammatory reaction that resolved with periocular steroids and topical NSAIDs. Systemic vasculitis and infectious diseases were ruled out and treatment was switched to aflibercept with no adverse effects being reported.